Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | BRS3 | P32247 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CDC25C | P30307 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9969469 | 0.83 | KMT2A (0.54) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL179124 | 0.80 | KMT2A (0.63) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL16788790 | 0.80 | KMT2A (0.50) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL19900671 | 0.79 | KMT2A (0.78) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL18213807 | 0.79 | KMT2A (0.55) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL10161660 | 0.77 | KMT2A (0.59) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL95792 | 0.77 | KMT2A (0.58) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL219769 | 0.77 | KMT2A (0.58) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL4573216 | 0.77 | KMT2A (0.58) | KMT2APOLBNOTUMRAB9ANPC1 | |
| SCHEMBL632993 | 0.77 | KMT2A (0.58) | KMT2APOLBNOTUMRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | KMT2A 1162/4885POLB 3173/4885NOTUM 512/4885 |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | KMT2A 4556/4885POLB 1822/4885NOTUM 2701/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KMT2A 1162/4885POLB 3173/4885NOTUM 512/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | KMT2A 4556/4885POLB 1822/4885NOTUM 2701/4885 |
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | KMT2A 4080/4885POLB 2990/4885NOTUM 4616/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | KMT2A 4703/4885POLB 1225/4885NOTUM 1965/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | KMT2A 4556/4885POLB 1822/4885NOTUM 2701/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KMT2A 1162/4885POLB 3173/4885NOTUM 512/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | KMT2A 864/4885POLB 1832/4885NOTUM 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.